BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 9595016)

  • 1. Survey on pretransfusion testing.
    Maffei LM; Johnson ST; Shulman IA; Steiner EA
    Transfusion; 1998 Apr; 38(4):343-9. PubMed ID: 9595016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. North American pretransfusion testing practices, 2001-2004: results from the College of American Pathologists Interlaboratory Comparison Program survey data, 2001-2004.
    Shulman IA; Maffei LM; Downes KA
    Arch Pathol Lab Med; 2005 Aug; 129(8):984-9. PubMed ID: 16048410
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incomplete pretransfusion testing leads to surgical delays.
    McWilliams B; Yazer MH; Cramer J; Triulzi DJ; Waters JH
    Transfusion; 2012 Oct; 52(10):2139-44; quiz 2145. PubMed ID: 22348700
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type and screen completion for scheduled surgical procedures. A College of American Pathologists Q-Probes study of 8941 type and screen tests in 108 institutions.
    Friedberg RC; Jones BA; Walsh MK;
    Arch Pathol Lab Med; 2003 May; 127(5):533-40. PubMed ID: 12708894
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Final bedside verification: results of a national survey of reagents and devices used in France].
    Noizat-Pirenne F; Le Pennec PY; Lascaux JM; Fraval D; Zaoui F; Rouger P
    Transfus Clin Biol; 1998 Dec; 5(6):392-6. PubMed ID: 9894330
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current state of transfusion practices for ABO-incompatible pediatric heart transplant patients in the United States and Canada.
    Dean CL; Sullivan HC; Stowell SR; Fasano RM; West LJ; Robitaille N; Josephson CD
    Transfusion; 2018 Sep; 58(9):2243-2249. PubMed ID: 30145826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The risk of an overt hemolytic transfusion reaction following the use of an immediate spin crossmatch.
    Shulman IA
    Arch Pathol Lab Med; 1990 Apr; 114(4):412-4. PubMed ID: 2322101
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Novel Monoclonal Antibody Therapeutics on Blood Bank Pretransfusion Testing.
    Mei Z; Wool GD
    Hematol Oncol Clin North Am; 2019 Oct; 33(5):797-811. PubMed ID: 31466605
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and cost-containment data that advocate abbreviated pretransfusion testing.
    Cordle DG; Strauss RG; Snyder EL; Floss AM
    Am J Clin Pathol; 1990 Oct; 94(4):428-31. PubMed ID: 2220670
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A prospective study to determine the safety of omitting the antiglobulin crossmatch from pretransfusion testing.
    Heddle NM; O'Hoski P; Singer J; McBride JA; Ali MA; Kelton JG
    Br J Haematol; 1992 Aug; 81(4):579-84. PubMed ID: 1390245
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Electronic verification of donor-recipient compatibility: the computer crossmatch.
    Butch SH; Judd WJ; Steiner EA; Stoe M; Oberman HA
    Transfusion; 1994 Feb; 34(2):105-9. PubMed ID: 8310478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A multicenter study on the performance of a fully automated, walk-away high-throughput analyzer for pretransfusion testing in the US population.
    Roback JD; Barclay S; Moulds JM; Denomme GA
    Transfusion; 2015 Jun; 55(6 Pt 2):1522-8. PubMed ID: 25753019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Transfusion Blood Bank (Recipient) Testing.
    Alquist CR; Helander L
    Clin Lab Med; 2021 Dec; 41(4):599-610. PubMed ID: 34689967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pretransfusion testing practices in North America, 2005-2010: an analysis of the College Of American Pathologists Interlaboratory Comparison Program J-survey data, 2005-2010.
    Downes KA; Shulman IA
    Arch Pathol Lab Med; 2012 Mar; 136(3):294-300. PubMed ID: 22372905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Experience with a cost-effective crossmatch protocol.
    Shulman IA; Nelson JM; Kent DR; Jacobs VL; Nakayama RK; Malone SA
    JAMA; 1985 Jul; 254(1):93-5. PubMed ID: 3999355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Containing costs in the blood bank by reducing unnecessary crossmatching.
    Friedman BA
    Pathologist; 1984 Jul; 38(7):405-10. PubMed ID: 10267505
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reactivity of FDA-approved anti-D reagents with partial D red blood cells.
    Judd WJ; Moulds M; Schlanser G
    Immunohematology; 2005; 21(4):146-8. PubMed ID: 16472014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Practical Solutions for Problems in Blood Grouping and Crossmatching.
    Andıç N
    Turk J Haematol; 2022 Feb; 39(1):55-60. PubMed ID: 34886658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The United Kingdom National External Quality Assessment Scheme (blood transfusion laboratory practice): trends in proficiency and practice between 1985 and 2000.
    Knowles SM; Milkins CE; Chapman JF; Scott M
    Transfus Med; 2002 Feb; 12(1):11-23. PubMed ID: 11967133
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Consecutive national surveys of ABO-incompatible blood transfusion in Japan.
    Fujii Y; Shibata Y; Miyata S; Inaba S; Asai T; Hoshi Y; Takamatsu J; Takahashi K; Ohto H; Juji T; Sagawa K
    Vox Sang; 2009 Oct; 97(3):240-6. PubMed ID: 19476605
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.